SecBot SecBot
8-K ·Filed Nov 12, 2026

KOD

Kodiak Sciences Inc.
BULLISH
Impact 6/10
Horizonweeks Processed4d 5h ago SEC0001193125-26-458248
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The DAYBREAK success de-risks the Zenkuda BLA submission due by year-end, but the rapid cash burn and thin equity base ($12.6M) mean the company will likely need additional capital before reaching profitability. Watch for the KSI-101 PEAK readout in December 2026 as the next major catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

KOD drug pipeline →

KSI-101

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 PEAK succeeds, a BLA submission would follow. The company expects Pivotal Analysis 2 data in Q2 2027, suggesting a potential BLA filing in 2027 and potential approval in 2028, though no official timeline has been given.
Next catalyst
None dated

What to watchThe December 2026 PEAK topline data is the key binary event to watch. If KSI-101 replicates the Phase 1b APEX signal (meaningful vision gains, rapid retinal drying) in the larger Phase 3 setting, it would validate the bispecific IL-6/VEGF approach and strengthen Kodiak's pipeline beyond Zenkuda. A miss or underwhelming result would be a significant negative given the elevated stock price and stretched cash position. The company's thin equity base ($12.6 million) and ~$66 million quarterly burn rate mean financing risk is high regardless of the readout outcome.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$111.19
T+0 close · Nov 12, 2026 · via day close
Latest settled
−9.41%
T+1 · $100.73
Vs SPY
−7.50%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $111.19entry
  2. T+1 · 15h ago −9.41%α −7.50% · $100.73
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kodiak Sciences reported Q3 2026 results with a net loss of $66.2M ($1.05/share), wider than the $61.5M loss in Q3 2025. The key positive was confirming that both Zenkuda and KSI-501 (tabirafusp-ted) met their primary endpoints in the Phase 3 DAYBREAK study, and the company is on track for a multi-indication BLA submission for Zenkuda by year-end and KSI-101 PEAK data in December 2026. Cash burn remains high, with cash dropping to $88.7M at quarter-end, partially offset by $69M in ATM proceeds raised after the quarter.

Key Financial Metrics

EPS
−$1.05

Key Facts

  • Zenkuda met the DAYBREAK primary endpoint (p=0.0007) with 54% of patients on 6-month dosing
  • Tabirafusp-ted (KSI-501) met DAYBREAK vision primary (p=0.0036) and anatomical key secondary (p<0.0001)
  • Multi-indication BLA for Zenkuda planned for Q4 2026
  • KSI-101 PEAK Pivotal Analysis 1 topline data expected December 2026
  • Q3 2026 net loss $66.2M vs $61.5M in Q3 2025
  • Cash and equivalents $88.7M at September 30, 2026
  • Raised $69M net proceeds from ATM after quarter end
  • Working capital $38.1M at September 30, 2026 vs $169.3M at December 31, 2025
  • Stockholders' equity $12.6M at September 30, 2026 vs $157.4M at December 31, 2025

Financial Impact

Q3 2026 net loss of $66.2M, cash burn of $121.2M in 9 months; $69M raised post-quarter via ATM

cashnet lossequity

Risk Factors

  • Cash runway limited: $88.7M at quarter-end plus $69M ATM proceeds may not support operations into 2027 as stated, given $66M+ quarterly burn
  • Stockholders' equity of only $12.6M raises going concern risk if additional financing is not secured
  • BLA approval for Zenkuda is not guaranteed despite positive Phase 3 data
  • KSI-101 PEAK results in December 2026 are a binary catalyst with significant upside/downside

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-458248
Document: kod-20261112.htm0001193125-26-458248
Document: 0001193125-26-458248-index-headers.html0001193125-26-458248
Document: 0001193125-26-458248-index.html0001193125-26-458248
Document: 0001193125-26-458248.txt0001193125-26-458248
8-K Data (Synthetic)0001193125-26-458248

Track record

13 reports on KOD

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +17.99% at T+20 after the Jun 11, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 5/10 Entry $104.93 Now $100.73 +4.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $109.50 Now $100.73 +8.01% settles Dec 15
  3. Nov 12, 20264d ago 8-K Bullish 6/10 Viewing Entry $111.19 Now $100.73 −9.41% settles Dec 14
  4. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $107.10 Now $100.73 −5.95% settles Dec 8
  5. Oct 20, 202627d ago S-3ASR Bearish 5/10 Entry $87.72 Now $100.73 −14.83% settles Nov 18
  6. Sep 30, 20266w ago SC 13D/A Bullish 7/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  7. Sep 30, 20266w ago Insider Buy Bullish 5/10 Entry $98.46 to $100.40 Now $100.73 +2.31% ▲ +1.97% +1.27% vs SPY
  8. Sep 28, 20267w ago 8-K Bullish 7/10 Entry $89.92 to $89.60 Now $100.73 +12.02% ▼ −0.36% −0.32% vs SPY
  9. Aug 13, 202613w ago 8-K Neutral 4/10 No price data
  10. Aug 13, 202613w ago Press Release Neutral 6/10 Entry $41.35 to $33.14 Now $100.73 +143.60% ▼ −19.85% −17.86% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens Wed (11h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026